Not FDA-approved1,4Evidence: Animal and lab onlyNot a peptideMetabolic and weight · Muscle

SLU-PP-3321,2

Not a peptide: a small molecule often looked up alongside peptides.

Key takeaway

SLU-PP-332 is a small synthetic compound, not a peptide, that switches on the estrogen-related receptors (ERRα, ERRβ and ERRγ), which help control energy use in muscle. Researchers describe it as an exercise mimetic.1,2 Its evidence comes from cells and mice: treated mice ran longer, and obese mice gained less fat and became more sensitive to insulin.2,3 No study in people and no FDA approval are reported in the sources reviewed here, and it is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.2,4,6

SLU-PP-332 at a glance

Substance typeNot a peptide. FDA’s substance registry records SLU-PP-332 as a chemical compound with the formula C18H14N2O2, and its developers describe it as a synthetic agonist they use as a chemical tool.1,2
What it isA synthetic agonist of all three estrogen-related receptors, most potent at ERRα, recorded by FDA’s substance registry as 4-hydroxybenzoic acid 2-(2-naphthalenylmethylene)hydrazide.1,2
FDA statusNo FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page does not list it.1,4
Human evidenceNone found: the published studies reviewed here used muscle cells and mice.2,3
Evidence strengthAnimal and lab studies only. The cited sources report no completed human study; the research base consists of animal, cell, or other laboratory work. How this label is assigned

What is SLU-PP-332?

SLU-PP-332 is a synthetic chemical compound, not a peptide. FDA’s substance registry records it as 4-hydroxybenzoic acid 2-(2-naphthalenylmethylene)hydrazide, with the formula C18H14N2O2.1

Its developers reported it in 2023 as an agonist of the estrogen-related receptors and as a chemical tool for studying them in animals.2

How is SLU-PP-332 thought to work?

Estrogen-related receptors are nuclear receptors that genetic studies link to muscle exercise capacity. SLU-PP-332 activates all three, with the greatest potency at ERRα, and in mice it switched on a set of genes typical of aerobic exercise.2

In obese mice it raised energy expenditure and the burning of fatty acids, effects the researchers compare with those of exercise.3

What do human studies show?

None of the sources reviewed here describes a study of SLU-PP-332 in people.2,3

In mice, it increased the share of oxidative muscle fibres and lengthened running endurance, an effect that depended on ERRα, according to the 2023 study.2

In mice made obese by diet or by a genetic defect, it reduced fat mass gain and improved insulin sensitivity, according to the 2024 study.3

What the evidence base contains

  • Animal or laboratory research A 2023 study in which SLU-PP-332 increased mitochondrial function in muscle cells and, in mice, increased oxidative muscle fibres and running endurance.2
  • Animal or laboratory research A 2024 study in obese mice in which it increased energy expenditure and fat burning, reduced fat gain and improved insulin sensitivity.3

Evidence-strength label: Animal and lab studies only. How this label is assigned

Is SLU-PP-332 FDA-approved?

None of the sources reviewed here reports an approval of SLU-PP-332 by FDA.1,4

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list SLU-PP-332.4

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. SLU-PP-332 is not among them.5,6

Timeline

  1. Researchers report SLU-PP-332 as a synthetic estrogen-related receptor agonist that increased exercise endurance in mice.2
  2. A study reports that SLU-PP-332 reduced obesity and improved insulin sensitivity in mouse models.3

What is still unknown?

Whether it has any of these effects in people, and whether it is safe: the studies reviewed here used cells and mice.2,3

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for SLU-PP-332: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for SLU-PP-332 are a bounded selection, not every registration or paper about SLU-PP-332. For the years before SLU-PP-332 was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list SLU-PP-332 as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name SLU-PP-332 in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

No FDA approval reported; studied only in cells and animals. Evidence comes from muscle-cell and mouse studies published in 2023 and 2024. SLU-PP-332 is not on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of SLU-PP-332?

No FDA approval reported; studied only in cells and animals. Evidence comes from muscle-cell and mouse studies published in 2023 and 2024. SLU-PP-332 is not on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗↗

The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
1
Source years
1
Drugs@FDA applications
0

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected clinical trial records, regulatory records, and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to SLU-PP-332?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

1Selected dated records
7Connected citations
1Populated source years2026
1/4Record lanes present

Registered human studies

Trial composition

0 of 0 selected trial records include at least one phase value; 0 of 0 include a status value in the retained structured contract.

PubMed bibliography

Publication composition

1 of 1 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
1

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 1 dated record

Research hub

Explore the SLU-PP-332 evidence record

Open all 1 records →
1Dated record
1Evidence type
1Cited public source
1Source year

Change ledger

Recently changed for SLU-PP-332

Open all 1 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling.

PubMed lists PMID 41850449 in International journal of biological macromolecules as Journal Article, with publication-date metadata of 2026-03-16 (day precision). PeptideScanner associated the retained record with the identity slug slu-pp-332. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
August 13, 2026
Evidence lane
Literature metadata

Official-source collections

Source records for SLU-PP-332

Open the full research atlas →

Evidence types

Coverage by source year

Selected records span August 13, 2026 to August 13, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration1,4
  • U.S. Department of Health and Human Services5
Dated updates connected to this profile · 1

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling.↗

    PubMed lists PMID 41850449 in International journal of biological macromolecules as Journal Article, with publication-date metadata of 2026-03-16 (day precision). PeptideScanner associated the retained record with the identity slug slu-pp-332. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    SLU-PP-332 (4-hydroxybenzoic acid 2-(2-naphthalenylmethylene)hydrazide) substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 16, 2026

  2. 2
    Synthetic ERRα/β/γ agonist induces an ERRα-dependent acute aerobic exercise response and enhances exercise capacity (2023) · PMID 36988910 ↗

    ACS Chemical Biology · Official source · Source checked November 16, 2026

  3. 3
    A synthetic ERR agonist alleviates metabolic syndrome (2024) · PMID 37739806 ↗

    The Journal of Pharmacology and Experimental Therapeutics · Official source · Source checked November 16, 2026

  4. 4
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  5. 5
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  6. 6
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026